Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Overactive bladder

From Wikipedia, the free encyclopedia
Condition where a person has a frequent need to urinate
Medical condition
Overactive bladder
Other namesOveractive bladder syndrome
SpecialtyUrology
SymptomsFrequent feeling of needing tourinate,incontinence
ComplicationsUTIs, anxiety
Usual onsetMore common with age[1]
DurationChronic
TypesAge-related, or Secondary to other illness
CausesOld age;detrusor muscle injury; over-consumption of water and caffeine; UTI; pelvic injury
Risk factorsOld age, obesity, caffeine, constipation
Diagnostic methodBased on symptoms after ruling out other possible causes[2][1]
Differential diagnosisOtherneurological conditions[2][1]
TreatmentPelvic floor exercises,bladder training, drinking moderate fluids,weight loss,[3] medications, Botox, surgery
MedicationAnticholinergic drugs, β3 agonists
PrognosisOften but not always incurable
Frequency~40% of elderly adults, increasing with age

Overactive bladder (OAB) is a common condition where there is a frequent feeling of needing tourinate to a degree that it negatively affects a person's life.[2] Overactive bladder is characterized by a group of four symptoms: urgency, urinary frequency,nocturia, and urge incontinence.

Urinary frequency is defined as urinating more than about 7-8 times in one day.[4] The frequent need to urinate may occur during the day,at night, or both.[5] The number of episodes varies depending on sleep, fluid intake, medications, and up to seven is considered normal if consistent with the other factors.[4]

In addition, patients with OAB experience urinary urgency, a sudden feeling that they have to get to the bathroom very quickly.

Lastly, they may experiencenocturia, which is waking up at night to urinate.[4]

Loss of bladder control (urge incontinence) is a form of urinary incontinence characterized by the involuntary loss of urine occurring for no apparent reason while feeling urinary urgency as discussed above, and often occurs with this condition.[1] This condition is also sometimes characterized by a sudden and involuntary contraction of the bladder muscles, in response to excitement or anticipation.

OAB is distinct fromstress urinary incontinence (SUI), but when they occur together, the condition is usually known as mixed urinary incontinence.[6] Treatment of mixed urinary incontinence usually focuses on the more bothersome component between OAB and SUI.[4]

Overactive bladder affects approximately 11% of the population and more than 40% of people with overactive bladder have incontinence.[7][8] Conversely, about 40% to 70% of urinary incontinence is due to overactive bladder.[9] Overactive bladder is not life-threatening,[1] but most people with the condition have problems for years.[1]

Pathophysiology

The cause of overactive bladder is unknown.[1] It is often associated with overactivity of thedetrusor urinae muscle, a pattern of bladder muscle contraction observed duringurodynamics.[10] Risk factors include obesity, caffeine, andconstipation.[7] Poorly controlleddiabetes, poorfunctional mobility, andchronic pelvic pain may worsen the symptoms.[1] People often have the symptoms for a long time before seeking treatment and the condition is sometimes identified by caregivers.[1]

Catheter-related irritation

[edit]

If bladder spasms occur or there is no urine in the drainage bag when acatheter is in place, the catheter may be blocked by blood, thick sediment, or a kink in the catheter or drainage tubing. Sometimes spasms are caused by the catheter irritating the bladder,prostate orpenis. Such spasms can be controlled with medication such asbutylscopolamine, although most people eventually adjust to the irritation and the spasms go away.[11]

Diagnosis

[edit]

Diagnosis of OAB is made primarily on the person's signs and symptoms and by ruling out other possible causes such asurinary tract infections, stones, bladder cancer orneurological conditions.[2][1][4]

Patients often complete a bladder diary, where they detail the frequency, timing and volume of each time they urinate, in addition to symptoms like urgency, leakage, and fluid intake which provides the provider detailed information about bladder health and function.[4]

For thorough evaluation, patients may require a cystoscopy to rule out anything abnormal within the bladder, and urodynamic testing to further test the bladder function and filling abilities.[4]

OAB causes similar symptoms to some other conditions such asurinary tract infection (UTI),bladder cancer, andbenign prostatic hyperplasia (BPH). Urinary tract infections often involve pain andhematuria (blood in the urine) which are typically absent in OAB. Bladder cancer usually includes hematuria and can include pain, both not associated with OAB, and the common symptoms of OAB (urgency, frequency, and nocturia) may be absent. BPH frequently includes symptoms at the time of voiding as well as sometimes including pain or hematuria, and all of these are not usually present in OAB.[12]Diabetes insipidus causes high frequency and volume, though not necessarily urgency.

Management

[edit]

Specific treatment of OAB is not always required.[1] If treatment is desired,pelvic floor exercises,bladder training, and other behavioral methods are initially recommended.[3]Weight loss in those who areoverweight, decreasingcaffeine consumption, and drinking moderate fluids, can also have benefits.[3] Medications, typically of theanti-muscarinic type, are only recommended if other measures are not effective.[3] Medications are no more effective than behavioral methods; however, they are associated with side effects, particularly in older people.[3][13] Third line therapy includes non-invasive tibial nerve stimulation, bladder botox injections and implantable sacral nerve stimulation devices.[4] Some non-invasive electrical stimulation methods appear effective while they are in use.[14]Urinary catheters orsurgery are generally not recommended.[3]

Lifestyle and behavioral therapy

[edit]

Behavioral and lifestyle changes are commonly recommended as the first-line option for treating overactive bladder. These include bladder training, which involves scheduled voiding (urination) and gradually increasing the time between bathroom visits. Pelvic floor exercises, known asKegel exercises, can help strengthen the muscles that control urination. Fluid management, which focuses on avoiding excessive caffeine and alcohol intake, is advised to reduce the rate at which the bladder fills and minimize irritation to the bladder. Weight management and maintaining a healthy diet contribute to overall bladder health, especially when weight loss is able to reduce abdominal compression of the bladder. Adopting these behavioral and lifestyle changes can often improve the condition and enhance the effectiveness of other treatment approaches.[15][16]

Most patients are not able to eliminate incontinence and other symptoms of OAB with lifestyle and behavioral modifications alone. However, numerous studies have demonstrated that these therapies are effective in improving quality of life, and some data shows that they increase the likelihood that medications can keep the OAB under control.[15]

Medications

[edit]

Medications are a common treatment option for people with overactive bladder syndrome. A number ofantimuscarinic drugs (e.g.,darifenacin,hyoscyamine,oxybutynin,tolterodine,solifenacin,trospium,fesoterodine) are frequently used to treat overactive bladder.[10] Long term use, however, has been linked todementia.[17]β3 adrenergic receptor agonists (e.g.,mirabegron,vibegron) may be used, as well.[18]

Patients taking Oxybutynin and other anticholinergic drugs experience a 70% reduction of incontinence episode frequency, on average. Approximately 1 in 4 patients experience complete dryness while taking oxybutynin. Therefore, medication management alone is sufficient for a substantial minority, butnot the majority, of patients with overactive bladder.[19]

Comparison of overactive bladder medication
AgentTraits
Oxybutynin (short-acting)
  • well known by physicians
  • available in market longer than other drugs for OAB
  • many studies provide support of effectiveness
  • available as generic in places including the United States
  • more side effects than alternatives, includingdry mouth andconstipation
  • severe dry mouth more often reported
  • user takes 2-3 pills a day
Oxybutynin (extended release)
  • fewer side effects than short-acting Oxybutynin
  • 1 pill per day
Oxybutynin (transdermal patch)
  • no pill
  • patch changed every 3–4 days
  • lower rate of dry mouth as compared to pill form
  • patch commonly causes skin irritation which can be severe
Oxybutynin (Topical medication)
  • fewer side effects than short-acting Oxybutynin
  • topical gel applied to abdomen, arms, or thighs daily
  • new on market
  • little existing research on this drug
Tolterodine (short-acting)
  • fewer side effects than short-acting Oxybutynin
  • 2 pills per day
  • 10% of Caucasians and 19% of black people have a genetic difference which causes them to lack a certain enzyme. Lack of this enzyme makes the drug less effective.
Tolterodine (extended release)
  • fewer side effects than short-acting Oxybutynin
  • 1 pill per day
  • 10% of Caucasians and 19% of black people have a genetic difference which causes them to lack a certain enzyme. Lack of this enzyme makes the drug less effective.
Solifenacin
  • 1 pill per day
  • More effective for some symptoms than Tolterodine
  • higher rates of constipation and dry mouth than tolterodine
  • less researched for safety and efficacy than Tolterodine and Oxybutynin
Trospium (short acting)
  • severe dry mouth less common than with oxybutynin
  • less researched for safety and efficacy than Tolterodine and Oxybutynin
Trospium (extended release)
  • 1 pill per day
  • little existing research on this drug
Darifenacin
  • 1 pill per day
  • less researched for safety and efficacy than Tolterodine and Oxybutynin
Fesoterodine
  • same metabolite asTolterodine, but does not require that enzyme to be active
  • it may avoid drug interactions of Tolterodine
  • little existing research on this drug

Procedures

[edit]

Botulinum toxin A (Botox) is approved by theFood and Drug Administration in adults with neurological conditions, includingmultiple sclerosis andspinal cord injury.[20] Botulinum Toxin A injections into the bladder wall can suppress involuntary bladder contractions by blocking nerve signals and may be effective for up to 9 months.[21][22] The growing knowledge of pathophysiology of overactive bladder fueled a huge amount of basic and clinical research in this field of pharmacotherapy.[23][24][25]

Overactive bladder may be treated with electrical stimulation, which aims to reduce the contractions of themuscle that tenses around the bladder and causes urine to pass out of it. Both invasive and non-invasive electrical stimulation procedures may be used to treat overactive bladder.[14]

Invasive surgeries

[edit]

If non-invasive and pharmacological approaches are not helpful, some people may be eligible for a surgical procedure to treat overactive bladder. Surgical options may includeurinary diversion,sacral neuromodulation, or augmentation cystoplasty.[26]

One surgical intervention, called a cystoplasty, involves the enlargement of the bladder using tissue taken from the patient'sileum, which is part of the small intestine. This procedure is rarely performed, and is only done for patients who have proven resistant to all other forms of treatment. This procedure can greatly enlarge urine volume in the bladder.[27]

Prognosis

[edit]

Because overactive bladder is most commonly associated with aging, the majority of patients experience symptoms (with or without incontinence) for the rest of their lives. A minority of age-related OAB cases may be cured or indefinitely suppressed by medications and behavioral modification. If the OAB is due to a different condition, such as aurinary tract infection, then symptoms should resolve after the underlying problem has been treated.[16]

Epidemiology

[edit]

Earlier reports estimated that about one in six adults in theUnited States andEurope had OAB.[28][29] The number of people affected with OAB increases with age,[28][29] thus it is expected that OAB will become more common in the future as the average age of people living in thedeveloped world is increasing. However, a recent Finnish population-based survey[30] suggested that the number of people affected had been largely overestimated due to methodological shortcomings regarding age distribution and low participation (in earlier reports). It is suspected, then, that OAB affects approximately half the number of individuals as earlier reported.[30]

The American Urological Association reports studies showing rates as low as 7% to as high as 27% in men and rates as low as 9% to 43% in women.[1] Urge incontinence was reported as higher in women.[1] Older people are more likely to be affected, and the number of symptoms increases with age.[1]

See also

[edit]

References

[edit]
  1. ^abcdefghijklmnAmerican Urological Association (2014)."Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline"(PDF). Archived fromthe original(PDF) on 26 April 2015. Retrieved1 June 2015.
  2. ^abcdGormley EA, Lightner DJ, Faraday M, Vasavada SP (May 2015). "Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment".The Journal of Urology.193 (5):1572–80.doi:10.1016/j.juro.2015.01.087.PMID 25623739.
  3. ^abcdefGormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE, Scarpero HM, Tessier CD, Vasavada SP (December 2012). "Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline".The Journal of Urology.188 (6 Suppl):2455–63.doi:10.1016/j.juro.2012.09.079.PMID 23098785.
  4. ^abcdefgh"Overactive Bladder".Your Pelvic Floor. Retrieved2025-09-26.
  5. ^"Urinary Bladder, Overactive". Retrieved1 June 2015.
  6. ^Harris, Shauna; Riggs, John (2024),"Mixed Urinary Incontinence",StatPearls, Treasure Island (FL): StatPearls Publishing,PMID 30480967, retrieved2024-03-07
  7. ^abGibbs, Ronald S. (2008).Danforth's obstetrics and gynecology (10 ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 890–891.ISBN 978-0-7817-6937-2.Archived from the original on 2016-03-05.
  8. ^Hargreaves, Emma; Baker, Katherine; Barry, Gill; Harding, Christopher; Zhang, Yingying; Kandala, Ngianga-Bakwin; Zhang, Xiaowen; Kernohan, Ashleigh; Clarkson, Carl E (2022-09-23). Cochrane Incontinence Group (ed.)."Acupuncture for treating overactive bladder in adults".Cochrane Database of Systematic Reviews.2022 (9) CD013519.doi:10.1002/14651858.CD013519.pub2.PMC 9502659.PMID 36148895.
  9. ^Ghosh, Amit K. (2008).Mayo Clinic internal medicine concise textbook. Rochester, MN: Mayo Clinic Scientific Press. p. 339.ISBN 978-1-4200-6751-4.Archived from the original on 2016-03-05.
  10. ^abSussman DO (September 2007). "Overactive bladder: treatment options in primary care medicine".The Journal of the American Osteopathic Association.107 (9):379–85.PMID 17908830.
  11. ^"Urinary catheters". MedlinePlus, the National Institutes of Health's Web site. 2010-03-09.Archived from the original on 2010-12-04. Retrieved2010-12-01.
  12. ^Wein A (October 2011)."Symptom-based diagnosis of overactive bladder: an overview".Canadian Urological Association Journal.5 (Suppl 2): S135–6.doi:10.5489/cuaj.11183.PMC 3193392.PMID 21989525.
  13. ^Ruxton K, Woodman RJ, Mangoni AA (August 2015)."Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis".British Journal of Clinical Pharmacology.80 (2):209–20.doi:10.1111/bcp.12617.PMC 4541969.PMID 25735839.
  14. ^abStewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL (December 2016)."Electrical stimulation with non-implanted electrodes for overactive bladder in adults".The Cochrane Database of Systematic Reviews.12 (2) CD010098.doi:10.1002/14651858.CD010098.pub4.hdl:2164/8446.PMC 6463833.PMID 27935011.
  15. ^abWhite, Nicola; Iglesia, Cheryl B. (2016-03-01)."Overactive Bladder".Obstetrics and Gynecology Clinics of North America. Medical and Advanced Surgical Management of Pelvic Floor Disorders.43 (1):59–68.doi:10.1016/j.ogc.2015.10.002.ISSN 0889-8545.PMID 26880508.
  16. ^abOuslander, Joseph; Reyes, Bernardo (2022). "Chapter 477: Caring for the Geriatric Patient".Harrison's Principles of Internal Medicine (21st ed.). New York: McGraw Hill.ISBN 978-1-264-26850-4.
  17. ^Araklitis G, Cardozo L (November 2017). "Safety issues associated with using medication to treat overactive bladder".Expert Opinion on Drug Safety.16 (11):1273–1280.doi:10.1080/14740338.2017.1376646.PMID 28889761.S2CID 10862256.
  18. ^Sacco E, Bientinesi R (December 2012)."Mirabegron: a review of recent data and its prospects in the management of overactive bladder".Therapeutic Advances in Urology.4 (6):315–24.doi:10.1177/1756287212457114.PMC 3491758.PMID 23205058.
  19. ^Diokno, Ananias; Ingber, Michael (Nov 2006)."Oxybutynin in Detrusor Overactivity".Urologic Clinics of North America.33 (4):439–445.doi:10.1016/j.ucl.2006.06.003.PMID 17011379.
  20. ^"FDA approves Botox for loss of bladder control".Reuters. 24 August 2008.Archived from the original on 24 September 2015.
  21. ^Chancellor, Michael B; Christopher Smith (August 2011).Botulinum Toxin in Urology.Springer.ISBN 978-3-642-03579-1.
  22. ^Sacco E, Paolillo M, Totaro A, Pinto F, Volpe A, Gardi M, Bassi PF (2008). "Botulinum toxin in the treatment of overactive bladder".Urologia.75 (1):4–13.doi:10.1177/039156030807500102.PMID 21086369.S2CID 208149855.
  23. ^Sacco E, Bientinesi R (2012). "Future perspectives in pharmacological treatments options for overactive bladder syndrome".Eur Urol Review.7 (2):120–126.
  24. ^Sacco E, Pinto F, Bassi P (April 2008). "Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences".International Urogynecology Journal and Pelvic Floor Dysfunction.19 (4):583–98.doi:10.1007/s00192-007-0529-z.PMID 18196198.S2CID 23846583.
  25. ^Sacco E, et al. (2009). "Investigational drug therapies for overactive bladder syndrome: the potential alternatives to anticholinergics".Urologia.76 (3):161–177.doi:10.1177/039156030907600301.PMID 21086288.S2CID 208148685.
  26. ^"Overview | Urinary incontinence and pelvic organ prolapse in women: management | Guidance | NICE".www.nice.org.uk. 2 April 2019. Retrieved2023-04-24.
  27. ^Scarneciu, Ioan; Lupu, Sorin; Bratu, Ovidiu Gabriel; Teodorescu, Andreea; Maxim, Laurian Stefan; Brinza, Adrian; Laculiceanu, Alexandru Georgian; Rotaru, Ruxandra Maria; Lupu, Aura-Mihaela; Scarneciu, Camelia Cornelia (2021-10-14)."Overactive bladder: A review and update".Experimental and Therapeutic Medicine.22 (6): 1444.doi:10.3892/etm.2021.10879.ISSN 1792-1015.PMC 8549091.PMID 34721686.
  28. ^abStewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (May 2003). "Prevalence and burden of overactive bladder in the United States".World Journal of Urology.20 (6):327–36.doi:10.1007/s00345-002-0301-4.hdl:2027.42/42170.PMID 12811491.S2CID 15994916.
  29. ^abMilsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ (June 2001). "How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study".BJU International.87 (9):760–6.doi:10.1046/j.1464-410x.2001.02228.x.PMID 11412210.S2CID 23650548.
  30. ^abTikkinen KA, Tammela TL, Rissanen AM, Valpas A, Huhtala H, Auvinen A (February 2007). Madersbacher S (ed.)."Is the prevalence of overactive bladder overestimated? A population-based study in Finland".PLOS ONE.2 (2) e195.Bibcode:2007PLoSO...2..195T.doi:10.1371/journal.pone.0000195.PMC 1805814.PMID 17332843.Open access icon

External links

[edit]
Diseases of theurinary tract
Ureter
Bladder
Urethra
Any/all
Pain
Control
Volume
Other
Eponymous
Classification
External resources
Authority control databases: NationalEdit this at Wikidata
Retrieved from "https://en.wikipedia.org/w/index.php?title=Overactive_bladder&oldid=1315493060"
Category:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp